Sutro Biopharma, Inc. (FRA:S090)

Sutro Biopharma Statistics

Total Valuation

Sutro Biopharma has a market cap or net worth of EUR 256.22 million. The enterprise value is 128.96 million.

Market Cap	256.22M
Enterprise Value	128.96M

Important Dates

The next estimated earnings date is Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	16.39M
Shares Outstanding	n/a
Shares Change (YoY)	+17.26%
Shares Change (QoQ)	+0.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	14.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.85
PB Ratio	-3.44
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.70
EV / Sales	1.44
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.67

Financial Position

The company has a current ratio of 2.53

Current Ratio	2.53
Quick Ratio	2.39
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.08
Interest Coverage	-3.77

Financial Efficiency

Return on equity (ROE) is -1,810.01% and return on invested capital (ROIC) is -256.77%.

Return on Equity (ROE)	-1,810.01%
Return on Assets (ROA)	-25.80%
Return on Invested Capital (ROIC)	-256.77%
Return on Capital Employed (ROCE)	-99.12%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	505,854
Profits Per Employee	-1.04M
Employee Count	178
Asset Turnover	0.32
Inventory Turnover	n/a

Taxes

In the past 12 months, Sutro Biopharma has paid 2.00 million in taxes.

Income Tax	2.00M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.96% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-16.96%
50-Day Moving Average	10.38
200-Day Moving Average	8.09
Relative Strength Index (RSI)	65.05
Average Volume (20 Days)	11

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.63

Income Statement

In the last 12 months, Sutro Biopharma had revenue of EUR 90.04 million and -184.75 million in losses. Loss per share was -22.05.

Revenue	90.04M
Gross Profit	123.05M
Operating Income	-116.38M
Pretax Income	-182.75M
Net Income	-184.75M
EBITDA	-109.93M
EBIT	-116.38M
Loss Per Share	-22.05

Balance Sheet

The company has 142.84 million in cash and 15.05 million in debt, with a net cash position of 127.79 million.

Cash & Cash Equivalents	142.84M
Total Debt	15.05M
Net Cash	127.79M
Net Cash Per Share	n/a
Equity (Book Value)	-74.38M
Book Value Per Share	-8.74
Working Capital	93.94M

Cash Flow

In the last 12 months, operating cash flow was -189.67 million and capital expenditures -2.20 million, giving a free cash flow of -191.86 million.

Operating Cash Flow	-189.67M
Capital Expenditures	-2.20M
Free Cash Flow	-191.86M
FCF Per Share	n/a

Margins

Gross margin is 136.66%, with operating and profit margins of -129.26% and -205.18%.

Gross Margin	136.66%
Operating Margin	-129.26%
Pretax Margin	-202.96%
Profit Margin	-205.18%
EBITDA Margin	-122.09%
EBIT Margin	-129.26%
FCF Margin	n/a

Dividends & Yields

Sutro Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.26%
Shareholder Yield	-17.26%
Earnings Yield	-72.11%
FCF Yield	-74.88%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 3, 2025. It was a reverse split with a ratio of 0.1.

Last Split Date	Dec 3, 2025
Split Type	Reverse
Split Ratio	0.1

Scores

Sutro Biopharma has an Altman Z-Score of -6.97 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.97
Piotroski F-Score	1